U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C7H9NO6S
Molecular Weight 235.214
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POMAGLUMETAD

SMILES

[H][C@@]12[C@@H](C(O)=O)[C@]1([H])S(=O)(=O)C[C@@]2(N)C(O)=O

InChI

InChIKey=AVDUGNCTZRCAHH-MDASVERJSA-N
InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1

HIDE SMILES / InChI
LY404039 [(-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid] is an agonist of orthosteric metabotropic glutamate receptor (mGluR)2/3. In addition, it acts as an agonist at dopamine D2 receptors. LY404039 demonstrated broad antipsychotic and anxiolytic efficacy across multiple animal models. LY-2140023 is a methionine amide prodrug of LY-404039 being developed by Eli Lilly & Co for the potential oral treatment of schizophrenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
149.0 nM [Ki]
92.0 nM [Ki]
80.0 nM [EC50]
Conditions
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
2007 Jan 25
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
2013 Aug
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
2013 May 22
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
2013 Nov
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
2015 Dec 1
Successes, failures, and future prospects of prodrugs and their clinical impact.
2019 Mar
Patents

Sample Use Guides

Phase 3 study for the treatment of schizophrenia: 40 mg LY2140023 (prodrug of LY404039) administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Mice: 3-30 mg/kg i.p.
Route of Administration: Oral
rat primary astrocytes were treated with 100 uM LY404039
Name Type Language
POMAGLUMETAD
Common Name English
LY-404039, (-)-
Code English
2-THIABICYCLO(3.1.0)HEXANE-4,6-DICARBOXYLIC ACID, 4-AMINO-, 2,2-DIOXIDE, (1R,4S,5S,6S)-
Common Name English
LY-404039
Code English
LY404039
Code English
Code System Code Type Description
WIKIPEDIA
Pomaglumetad
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY
PUBCHEM
9834591
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID40212943
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY
FDA UNII
531QUG7P9E
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY
CAS
635318-11-5
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY
CHEBI
94640
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL375611
Created by admin on Fri Dec 15 18:12:10 GMT 2023 , Edited by admin on Fri Dec 15 18:12:10 GMT 2023
PRIMARY